In April 2020, MVM led the growth investment round in SkyCell, a company that has developed patented temperature-control technology to safely transport vaccines and biotechnology drugs by air. SkyCell technology avoids the need for active refrigeration, lowers the costs of transport and reduces potential damage to vital pharmaceutical products.

MVM’s Hugo Harrod and Jack Tanaka will join the SkyCell board.